The emergence of resistance to fluoroquinolones in virtually all species of bacteria was recognized soon after the introduction of these compounds for clinical use more than 10 years ago. Various resistance mechanisms, often interdependent, may explain different levels of resistance. Epidemiological factors, local antibiotic policies, patients' characteristics, origin of the strains, and geographic location are among the factors contributing to highly variable resistance rates. During the last several years, resistance to fluoroquinolones has remained very high among methicillin-resistant Staphylococcus aureus strains and in intensive care unit patients, and it has increased among nosocomial isolates of Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa. More worrisome are recent reports of an overall increase in resistance to fluoroquinolones among bacteria responsible for community-acquired infections, such as Escherichia coli, Salmonella species, Campylobacter species and Neisseria gonorrhoeae.
The introduction of fluoroquinolones more than 10 years ago offered clinicians orally or parenterally administrable compounds with a broad spectrum of activity and therapeutic results not seen before for a wide range of infections, including complicated urinary tract infections, gastrointestinal infections, sexually transmitted diseases, respiratory tract infections, and chronic osteomyelitis [1] [2] [3] [4] . Extensive use and misuse of these compounds in both human and veterinary medicine led to the emergence and spread of resistant strains.
Widely varying percentages of resistance to fluoroquinolones have been associated with particular bacterial species, clinical settings, origins of strains, geographic locations, and local antibiotic policies [1, [5] [6] . This article reviews the epidemiology of resistance to fluoroquinolones among bacteria responsible for community-acquired and nosocomial infections.
Features of Bacterial Resistance to Fluoroquinolones

Genetic Aspects
Resistance to fluoroquinolones is chromosomally mediated; previous reports of plasmid-mediated resistance have not been confirmed. Acquired resistance is due to different mechanisms [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , involving mutations either in the structural genes governing the target of fluoroquinolones DNA gyrase (gyrA or gyrB) or topoisomerase IV or in the regulatory genes governing bacterial permeability or the efflux capacity of the bacteria.
Multiple mutations may occur within a single chromosomal gene, resulting in mutants associated with variable MICs [21] [22] [23] 28] ; for gyrA in Escherichia coli, different substitutions of one or several amino acids result in quite a large number of phenotypes, for which the MIC range of ciprofloxacin is 0.05-64 ti,g/mL [14] .
Gyrase mutations have been identified as the main mechanisms of resistance to fluoroquinolones in all bacterial species, while topoisomerase IV mutants have been noted only in E. coli and Neisseria gonorrhoeae. Very recently, a mutational alteration of a new topoisomerase, grlA, has been noted in Staphylococcus aureus; these mutants are associated with a very small increase in MICs [29] . Permeability mutants, present only in gram-negative bacteria, may give rise to increased MICs of fluoroquinolones and of some unrelated antibiotics such as 0-lactam drugs, tetracyclines, and chloramphenicol (as in mutants of Enterobacteriaceae species or soxRS mutants of Pseudomonas aeruginosa) [20, 27] .
Active efflux has been noted in S. aureus (NorA) and many gram-negative bacteria, including species of Enterobacteriaceae (marA), Pseudomonas species, and Campylobacter species. This mechanism involves mostly hydrophilic fluoroquinolones (such as norfloxacin and enoxacin) rather than pefloxacin. In addition to fluoroquinolones, this resistance mechanism affects the activity of unrelated antibiotics such as tetracyclines, chloramphenicol, and 0-lactam drugs, as well as other structurally diverse substances such as cetrimide, benzalkonium chloride, acriflavine, and ethidium bromide [29] .
The regulation of these resistant genes is extremely complex and involves many genes, promoters, and suppressors, the activity of which can be induced by various unrelated substances, including salicylates (see [30] for references). One of the most important features of bacterial resistance to fluoroquinolones is the ability to accumulate several mutations, affecting both DNA gyrase and bacterial permeability and resulting in strains associated with very high MICs (e.g., MICs of ciprofloxacin of 32-1,024 sg/mL). Such strains have been observed among isolates of S. aureus, Enterobacteriaceae species, and P. aeruginosa [21, 28] . to 10-10 and is related to the bacterial species, the selecting agent, and the antibiotic concentration. Resistant mutants can be selected in vitro and in vivo only if the concentration of the antibiotic is less than 8-fold the MIC [29, 31] . Resistant mutants selected with any fluoroquinolone are cross-resistant to the other compounds but at quite variable levels; nalidixic acidresistant mutants are usually susceptible to ciprofloxacin despite an increase in the MIC of the latter drug from 0.01 to 0.1 ug/mL. This may also be true for some strains with lowlevel resistance to pefloxacin or lomefloxacin, which may remain susceptible to ciprofloxacin (table 1) [5, 11, 32] . Some mutants with a very low level of resistance may remain undetectable by routine MIC determinations. However, it is important to identify them since they are prone to be selected for a higher MIC. Fluoroquinolone-resistant mutants resulting from a permeability or efflux mechanism may be selected by other, unrelated antibiotics or substances. Some new fluoroquinolones that are highly effective against S. aureus in vitro may remain so within achievable therapeutic ranges (MIC, 0.5 p,g/mL) against ciprofloxacin-resistant S. aureus. This is the case with the new fluoroquinolone clinafloxacin [33] .
From a clinical point of view, however, it should be stressed that such strains with borderline susceptibility may necessitate a modification of standard therapeutic regimens in order to minimize the risk of selection of a highly resistant strain [34, 35] . A resistant strain selected during therapy may be responsible or not for a clinical failure. However, depending upon epidemiological factors and virulence traits, this resistant clone may further disseminate to other patients. The difference in the in vitro activity of the fluoroquinolones suggests that comparative epidemiological studies must involve the same compound with the same susceptibility breakpoints.
Fluoroquinolone Use and Emergence and Spread of Resistance
Ciprofloxacin is the most used antibiotic in the world, and fluoroquinolones in general are very widely used in human and veterinary medicine. Compounds administered to animals are either identical (e.g., ofloxacin) or very similar to those given to humans; enrofloxacin, used for animals in many European countries, is a derivative of ciprofloxacin [11, [36] [37] [38] .
Whether fluoroquinolones are given to animals for medical reasons or as growth promoters, fluoroquinolone-resistant bacteria (such as Salmonella or Campylobacter species) are isolated from animals and can be transmitted to humans [26, 38, 39] . Proposed restrictive measures have not yet been applied in veterinary medicine [40] . Restrictive use by humans has also been widely proposed, but avoiding the use of such valuable compounds would be difficult. In addition, the impact of such action on the dissemination of resistance has not yet been established [41] , since the epidemiology of resistance is multifactorial.
For example, most of the patients from whom fluoroquinolone-and methicillin-resistant S. aureus is isolated have never been treated with a fluoroquinolone [11, 42] . Local epidemiological factors may contribute to the spread of resistant clones. These factors include the lack of antibacterial policies; use of compounds with poor activity, at a low dosage and for prolonged periods; and lack of specific measures to counteract the spread of these resistant strains.
Evolution of Bacterial Resistance to Fluoroquinolones
The incidence of resistance to fluoroquinolones has dramatically increased in the past 10 years in particular bacterial species and clinical settings and where certain local factors were involved [11, 12, 38, [43] [44] [45] . There is a striking difference between bacteria isolated from patients with communityacquired vs. nosocomial infections due to either gram-positive or gram-negative organisms [11, 12] .
Gram-Positive Bacteria
S. aureus. The incidence of fluoroquinolone resistance in S. aureus is not easy to delineate, since in many reports the origin of the strains and/or their resistance to methicillin is not indicated [11, 31] .
Nosocomial S. aureus strains. By -2-4 years after the introduction of fluoroquinolones for clinical use, most methicillin-resistant S. aureus isolates from clinical specimens were resistant to fluoroquinolones (table 2) [6, 11, 46, 47] . These bacteria either were the cause of infections or were responsible for colonization in patients receiving or not receiving fluoroquinolones.
Isolation of fluoroquinolone-and methicillin-resistant S. aureus has now been reported from virtually all countries (table 3) [5, 6, 30, 43, 46, [48] [49] [50] [51] [52] [53] [54] [55] [56] . In all cases, resistance is due to the spread of 1-2 clones among 5-8 different clones present in a hospital; these epidemic clones of methicillinresistant S. aureus have potential to spread because of resistance to antibiotics and antiseptics [11, 29- Community-acquired S. aureus. Fluoroquinolone-resistant, methicillin-susceptible S. aureus organisms are rarely isolated in cases of community-acquired infection; such organisms, which represent <5% of all methicillin-susceptible S. aureus isolates, are usually recovered from nosocomial infections [11, 47] .
Streptococcus pneumoniae. In many countries, ciprofloxacin and ofloxacin have been released for the treatment of lower respiratory tract infections, including pneumococcal pneumonia. In France only sparfloxacin is used for such infections. Fluoroquinolones have borderline activity against S. pneumoniae, with MIC50 values overlapping the susceptibility breakpoints for ciprofloxacin and ofloxacin. For this reason, comparative studies must always take into account actual MIC values; resistance percentages based upon breakpoint MICs are useless.
Highly resistant strains of S. pneumoniae have already been described, and it will be important to follow their incidence with regard to new, investigational fluoroquinolones. These compounds are eightfold to 32-fold more effective than ciprofloxacin/ofloxacin, but only a few of them (clinafloxacin and trovafloxacin) are in the early stages of clinical testing [11, 32, [57] [58] [59] [60] [61] . Because of their higher intrinsic activity, these investigational compounds should clearly differentiate strains with acquired resistance (MIC, >4 i.tg/mL) from strains with normal susceptibility (MIC, 0.06-0.25 pg/mL). Enterococcus faecalis. E. faecalis strains that are resistant to most antimicrobial agents, including vancomycin, have been isolated with increasing frequency from patients with nosocomial infections in Great Britain and the United States [11, 13] . In contrast to the older fluoroquinolones, which were not indicated for the treatment of enterococcal infections (except possibly urinary tract infection), new fluoroquinolone compounds have much better activity. It is therefore particularly disquieting that strains highly resistant to ofloxacin/ciprofloxacin, usually linked to high-level gentamicin resistance (M. D. Kitzis, personal communication), are being isolated in many hospitals; this circumstance will curtail future use of the newer fluoroquinolones [62] .
Gram-Negative Bacteria
Since fluoroquinolones were initially directed mainly against gram-negative bacteria, it is not surprising that a huge amount of data concerning the resistance of most clinically relevant bacterial species to fluoroquinolones has become available.
Enterobacteriaceae: community-acquired infections. As reported following a recent multicenter study in the United States [13] (table 4) , fluoroquinolones are assumed to be highly effective against virtually all E. coli, Klebsiella species, Proteus mirabilis, and Salmonella species organisms. This is still true in many countries, where >98% of E. coli isolates are susceptible to ciprofloxacin; however, alarming reports concerning Table 4 . Data from a multicenter study of the in vitro activity of ciprofloxacin against gram-negative bacteria [13] . fluoroquinolone-resistant Enterobacteriaceae organisms in developed and developing countries are becoming more and more frequent [6-15, 46, 63-65] . Ciprofloxacin-resistant salmonellae are isolated with increasing frequency: resistance of up to 39.6% has been reported for Salmonella haddar isolates in Great Britain, in comparison with a 2% rate 3 years before [38] . Of particular interest are the recent reports concerning fluoroquinolone-resistant Salmonella typhi, since the fluoroquinolones have dramatically modified the treatment of typhoid fever [38] . Resistance among Shigella species is still very low (<5%) , except in China, where up to 50% of Shigella dysenteriae, Shigella sonnei, and Shigella boydii isolates are resistant to fluoroquinolones, reflecting the spread of such highly epidemic strains [11] [12] [13] [65] [66] [67] [68] [69] [70] .
E. coli isolates from patients with urinary tract infection still display >98% susceptibility to fluoroquinolones in most developed countries. However, a dramatic increase in the percentage of resistant strains has been documented more frequently, particularly in France and Spain, where investigators have found that up to 10% of strains are resistant [9, [11] [12] [13] . Resistance is at worrisome levels in some developing countries where there is access to fluoroquinolones: up to 14% in some South American countries, 25% in Korea and the Philippines, and up to 52.9% in China [11, 12, 47] .
Enterobacteriaceae: nosocomial infections. A dramatic increase in the percentage of fluoroquinolone-resistant enterobacteria has been observed in many European countries [9, 11] . Several factors may contribute to this increased resistance and also may explain major differences in resistance rates. Fluoroquinolones are still considered to be the first-line antimicrobials for treatment of urinary tract infection due to multidrug-resistant bacteria. These drugs are used to treat urinary tract infections due to Klebsiella pneumoniae that produce extended spectrum 0-lactamase agents. More than 40% of fluoroquinolone-resistant strains of K. pneumoniae are reported from France and a few other countries [11] .
A multidrug-resistant strain has a definite potential to be selected and disseminate in the hospital environment; such is the case with Serratia marcescens, of which >50% of isolates are resistant to fluoroquinolones. A high percentage of resistance to fluoroquinolones may also be observed in other nosocomial bacteria, such as Enterobacter species, Citrobacter freundii, and indole-positive Proteus species (tables 1 and 5).
The incidence of fluoroquinolone-resistant Enterobacteriaceae organisms is extremely high in particular clinical settings, such as intensive care units, and among certain patients, such as those with cancer who are receiving fluoroquinolones as prophylaxis [11, 41, 48, 51, 72] . One of the most interesting means of studying resistance to fluoroquinolones is following resistance rates in institutions where patients' characteristics and methodologies have not changed over a period of several years. In comparison with local incidental reports, such studies demonstrate better the trends in fluoroquinolone resistance (table 2) .
P. aeruginosa. The greatest range in resistance rates is observed among P. aeruginosa isolates [6, 46, 48] : they vary from 5% to >50%, depending on the origin of the strains [9, 11-13, 15, 27, 72] . P. aeruginosa is associated with the same problems common with other nosocomial bacteria: local epidemics, multidrug-resistant strains, and dissemination in particular clinical settings such as intensive care units. Fluoroquinolones, the only antibiotics administered orally, are often used at a dosage that is too low against P. aeruginosa. In some hospitals the use of ciprofloxacin is restricted, and as a consequence, much-less-effective compounds which are more likely to select resistant mutants are used.
Acinetobacter species. Acinetobacter species isolates from patients with nosocomial infections, particularly those in intensive care units, are often (10%-40%) resistant to fluoroquinolones [11, 13] .
Haemophilus influenzae. After nearly 10 years of fluoroquinolone use, the first isolation of H. influenzae resistant to fluoroquinolones was reported in 1994 [73] . During the past 2 years, however, there have been an increasing number of reports concerning fluoroquinolone-resistant H. influenzae, and a resistance rate of 3%-4% was noted in a recent study in the United States [13] .
Moraxella catarrhalis. Fluoroquinolones are highly effective against M catarrhalis (MIC90, <0.03 //g/mL). There has been a recent report of a fluoroquinolone-resistant M catarrhalis isolate recovered during therapy with ciprofloxacin (MIC, 8 btg/mL) [74] .
N. gonorrhoeae. Fluoroquinolones are recommended by the Centers for Disease Control and Prevention and used worldwide as first-line treatment for gonococcal infections [3] . During the past 5 years, an increasing number of publications from the United States, Japan, Hong Kong, Southeast Asia, Australia, and Africa [75 -78] have indicated an increase in the MIC50 and MIC90 values of fluoroquinolones; respective increases from 0.008 tg/mL and 0.06 iig/mL in 1983 to 0.03 and 0.5 ,ug/mL in 1994 were noted in a recent study in Japan [77] . Clinical failures of treatment with fluoroquinolones against gonococcal strains in the United States, Australia, Hong Kong, and the United Kingdom have also been reported [78] (MICs of ciprofloxacin and ofloxacin, 2-8 pg/mL). One of the factors that may have contributed to the isolation of such resistant strains is the use of compounds with poor activity and at a low dosage in developing countries where treatment with a more effective compound would be too expensive for patients.
Campylobacter jejuni and Campylobacter coli. The most striking increase in resistance to fluoroquinolones among community-acquired bacteria has been observed in C. jejuni and C. coli isolates, for which rates exceed 30% in many reports and are up to 57% in Spain [11, 26, 45, [79] [80] [81] [82] . Fluoroquinoloneresistant Campylobacter species have been isolated from both humans and animals and are clearly linked to fluoroquinolone use in veterinary medicine.
Conclusions
Highly divergent rates of fluoroquinolone resistance in both community-acquired and nosocomial pathogens have been reported worldwide. Many factors, including patients' characteristics, local epidemiological factors, antibiotic policies, inadequate usage, lower standards of living in developing countries, lack of information, and use in animals may be responsible for such divergent data.
Multistep selection of resistant strains resulting from the association of different resistance mechanisms is responsible for the emergence of high-level resistance to fluoroquinolones. For this reason, recognition of strains with low-level resistance is important in order to modify standard therapeutic regimens.
As clearly demonstrated in vitro, selection of a resistant clone is more likely to occur with use of the less effective compounds. All the resistant mutants selected with one compound display cross-resistance to the other compounds but at a variable MIC level. High-level resistance is particularly worrisome since such bacteria are already resistant to or have reduced susceptibility to new, investigational compounds, thus curtailing future use of these promising agents.
Once resistant strains are selected, they may spread in the community or in the hospital environment if they have epidemic potential (as do salmonellae and pneumococci) or if favorable conditions exist. Follow-up of fluoroquinolone resistance is mandatory and should be performed everywhere, including in individual communities, in order to better manage infections and counteract the spread of resistant strains.
